Cargando…
Managing Dry Eye Disease and Facilitating Realistic Patient Expectations: A Review and Appraisal of Current Therapies
Dry eye disease (DED) is a multifactorial disease of the ocular surface characterized by loss of homeostasis of the tear film and accompanied by ocular signs and symptoms such as corneal and conjunctival damage, patient discomfort, and visual disturbance. The prevalence of DED ranges from 5%−33%. Pa...
Autores principales: | Shen Lee, Bridgitte, Kabat, Alan G, Bacharach, Jason, Karpecki, Paul, Luchs, Jodi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6969676/ https://www.ncbi.nlm.nih.gov/pubmed/32021076 http://dx.doi.org/10.2147/OPTH.S228838 |
Ejemplares similares
-
Effect of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, on Corneal Staining in Patients With Keratoconjunctivitis Sicca: A Pooled Analysis of Phase 2b/3 and Phase 3 Studies
por: Malhotra, Ranjan, et al.
Publicado: (2019) -
Selective Pharmacologic Therapies for Dry Eye Disease Treatment: Efficacy, Tolerability, and Safety Data Review from Preclinical Studies and Pivotal Trials
por: Shen Lee, Bridgitte, et al.
Publicado: (2022) -
Effect of OTX-101 in Patients with Dry Eye Disease at Day 14 of Treatment: Ocular Surface Endpoint Results from the Phase 2b/3 Clinical Trial
por: Schechter, Barry A, et al.
Publicado: (2022) -
A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease
por: Tauber, Joseph, et al.
Publicado: (2018) -
Making the diagnosis of Sjögren’s syndrome in patients with dry eye
por: Beckman, Kenneth A, et al.
Publicado: (2015)